Improvement of refractory migraine headache by propofol: case series by Hassan Soleimanpour et al.
Soleimanpour et al. International Journal of Emergency Medicine 2012, 5:19
http://www.intjem.com/content/5/1/19CASE REPORT Open AccessImprovement of refractory migraine headache by
propofol: case series
Hassan Soleimanpour1*, Aliakbar Taheraghdam2, Rouzbeh Rajaei Ghafouri1, Ali Taghizadieh1,
Karim Marjany3 and Maryam Soleimanpour4Abstract
Background: Several studies have been conducted on managing migraine headaches and developing effective
medications for decreasing migraine-associated pain.
Case presentation: Intravenous propofol was prescribed (10 mg every 5 min) for eight patients with intractable
migraine headaches visiting the Emergency Department. The average pain score experienced by patients was
recorded using the Visual Analogue Scale at the beginning of the treatment procedure and following the injection
for 30 min (5-min intervals). The patients’ reported pain scores decreased significantly (P= 0.01) from 8.87 ± 0.83 (CI:
8.17, 9.57) to 1.12 ± 0.83 (CI: 0.43, 1.82) before and 30 min following the injection.
Discussion: It seems that in the treatment of intractable migraine headaches, GABAergic receptors, compared to
the normal conditions, have a lower activity status.
Conclusion: Because of the high tendency of propofol to GABAergic receptors, it probably changes this
physiological condition by activating the receptors, which results in a significant pain reduction.
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The International Association of Headache introduced
acetaminophen and NSAIDs as common treatments for
mild to moderate migraines, and selective 5-HT agonists
(triptans) in more severe cases [1]. However, one of the
major problems in the treatment of migraines is refrac-
tory migraine headache or migraine pain lasting more
than 72 h [2]. Among the various studies that have been
conducted worldwide on the treatment of refractory mi-
graine headaches, few have been carried out on the role
of propofol in the treatment of such migraine headaches.
Propofol (2, 6 di-isopropyl phenol) has been used as a
rapid- and short-acting intravenous medication for the
induction of anesthesia and procedural sedation for
many years. Its pharmacologic mechanism is related to
the agonist effect on gamma-aminobutyric acid (GABA)
receptors [2]. This study evaluates the role and efficiency* Correspondence: soleimanpourh@tbzmed.ac.ir
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reproduction in any medium, provided the origof intravenous propofol in several patients presenting to
the emergency department.Case presentation
In this study, eight patients who presented to the emer-
gency department, Imam Reza Hospital, Tabriz Univer-
sity of Medical Sciences, Tabriz, Iran with headaches
were examined [3]. These patients had previously used
different medications to alleviate their pain, but had
experienced no improvement, and the subjects still com-
plained of severe headaches. At first, the patients’ histor-
ies were taken, and complete examinations (general and
neurological) were performed. Based on the Inter-
national Headache Society (IHS) criteria, the subjects
were diagnosed with migraines [1]. The migraine head-
aches in all these eight patients had lasted more than
72 h and had not responded to common treatments
(triptans, dexamethasone, opioids and NSAIDs). After
diagnosis of migraine headaches for these patients, the
manner of using medications, the reason for its prescrip-
tion and the possible side effects were explained to
them, and it was emphasized that propofol is safe andThis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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from them. Of these eight patients, six were female and
two were male, and their average age was 30.5 years old.
All patients had experienced migraines for several years.
Using a rating scale numbered from 0 to 10 (Visual
Analogue Scale, VAS), patients were asked to record
their perceived pain on paper (Table 1). In these
patients, IV propofol (Propofol-Lipuro 1%, B. Braun)
was injected as 10-mg bolus doses every 5 min until
achievement of therapeutic response [2]. Severity of the
patients’ headaches was measured and recorded every
5 min. The severity of pain based on the VAS on pre-
senting to the ED was reported as 10/10 by two patients,
9/10 by three patients and 8/10 by the other three
patients. On this basis, the average severity of pain at
presentation was 8.87 ± 0.83 (CI: 8.17, 9.57). Thirty min-
utes after treatment, the average severity of pain in
patients decreased to 1.12 ± 0.83 (CI: 0.43, 1.82)
(P= 0.01). Before starting treatment, all patients com-
plained of nausea, and five had vomited. Furthermore,
four patients complained of photophobia and phonopho-
bia. In all cases, after treatment, concomitant problems
such as nausea, vomiting, photophobia and phonophobia
had completely resolved. One patient experienced a brief
period of drowsiness for 10 min, and in another case,
oxygen saturation dropped to 89%, which was appropri-
ately managed by nasal O2. Adverse events such as
decreased levels of consciousness, changes in blood
pressure, tachycardia or bradycardia were not recorded
in any of the patients. All patients were followed up by
phone for 72 h after release from the ED. Of eight
patients being followed up during this time period, six
never experienced headache recurrence again and
remained without symptoms. However, case 1 experi-
enced a headache and 24 h later rated his pain as 5/10;
it was relieved by NSAIDs. Case 8 experienced headache
recurrence 36 h later and rated her pain as 4/10. This
pain was also appropriately relieved by NSAIDS.
In the mentioned cases (1 and 8) there was no need
for re-admission to the ED and receiving IV medicationsTable 1 Demographic characteristics of patients






1 Male 22 10/10 2/10 50
2 Female 44 9/10 0/10 10
3 Female 35 8/10 2/10 20
4 Female 28 10 /10 1/10 20
5 Female 25 8/10 1/10 30
6 Male 28 8/10 0/10 30
7 Female 32 9/10 1/10 20
8 Female 30 9/10 2/10 60since the severity of the pain was less than at the first
presentation to the ED (VAS= 10/10 and 9/10).
Discussion
So far, little work has been done regarding the role of
propofol in the treatment of migraine headaches. Com-
mon medications used for the treatment of this kind of
headache include opioids, NSAIDs, ergotamine com-
pounds, triptans, antiemetics and other analgesics. Dur-
ing acute migraine attacks because of absorption
disorders (even in the absence of nausea and vomiting),
the intravenous route is preferred [2].
Prescription of intravenous propofol in subanesthetic
doses in these eight patients caused pain relief for refrac-
tory migraine headaches. Propofol is a medication that is
often used for inducing anesthesia in the operating room
[3-6]. The effect of propofol on GABA receptors has
been well proved by evidence from different studies [2].
Propofol inhibits afferent sympathetic action and cardiac
baroreceptor reflexes [7,8]. Another study demonstrated
that the effect of this medication on EEG during sed-
ation with low doses is limited to the frontal lobe of the
brain [9].
Also, another study indicated a global decrease in me-
tabolism of CNS [10]. Its pharmacological mechanism is
due to an agonist effect on gamma-aminobutyric acid
(GABA) receptors [2].
It seems that the therapeutic effects of propofol are
due to its effects on the chloride channels in the β1-
subunit of GABA receptors [11].
Drummond et al. also reported the successful treat-
ment of two cases of resistant migraine headache with
intravenous propofol [12].
Krusz et al. reported the first study of propofol use for
headaches in 2000. This study indicated that 82 percent
of patients were completely pain free. In the rest of them
the pain decreased between 50 to 90 percent. None of
the subjects experienced any drowsiness or disorienta-
tion after propofol prescription. Only a few patients had
transient lethargy and unintelligible language (4–3 min),Required time until palliation
of headache (min)
Co-existing symptoms
25 Nausea, vomiting, photophobia
5 Nausea
10 Nausea, vomiting, photo/phonophobia
10 Nausea
15 Nausea, vomiting, photo/phonophobia
15 Nausea
10 Nausea, vomiting
30 Nausea, vomiting, photo/phonophobia
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ments. The researchers concluded that propofol can be
used in the clinic or emergency department as a defini-
tive therapy for treatment-resistant migraines without
side effects. In this study, the dramatic effect of propofol
on pain relief in refractory migraine headaches was men-
tioned to be due to the high affinity of propofol to
GABA receptors, which have a low activity status in
migraines. Propofol, by stimulating these receptors,
overcomes this physiological process and, as a result, mi-
graine headaches can be cured. Researchers also consid-
ered using other medications with the same mechanism
(GABA stimulators) as potential medications in treating
migraine headaches and other types of headaches; this
requires more research and investigation [2].
Furthermore, there are several other reports demon-
strating the efficacy and good therapeutic effects of
intravenous propofol in the treatment of refractory
migraines [13].
As compared with other similar studies, because of its
quite large sample size the present study is of significant
importance for the assessment of intravenous propofol’s
efficacy in the treatment of intractable migraine head-
aches (case series).
Also, there are studies that investigated the role of
propofol in the treatment of non-migraine-type chronic
headaches. For example, in a study that was conducted
on patients with daily chronic headaches resistant to
common treatments, more than 90% of patients showed
significant improvements in their headaches, and also no
symptoms have been reported. Based on the results of
this study, propofol administration under reliable moni-
toring and in controlled conditions was suggested for
daily chronic headaches [14].
High efficiency of intravenous propofol in the treat-
ment of acute resistant migraine headaches can pave the
way for new treatments in the field of migraine head-
aches and also be an appropriate replacement for other
common medications for the treatment of migraines.
With more complementary research, it will be possible
to introduce this medication as a new and quite effective
medication in the treatment of acute migraine headaches
because of its wonderful effect of decreasing pain, rapid
onset of action, safety and few side effects. However,
there are still many questions about the pathophysiology
and exact mechanism of migraines, and more studies are
required to explore this field.
Conclusion
It seems that in refractory migraine headaches, GABAer-
gic receptors are in a lower activity status [2]. Because of
the high tendency of propofol to these receptors, it
probably changes this physiological condition by activat-
ing the receptors, which results in a significant painreduction. Therefore, propofol can be introduced as a
medication that is effective, rapid-acting, safe and with
few side effects for relieving acute migraine headaches.
Consent
Every aspect of the present study was explained to the
patients, and we obtained their written consent for par-
ticipation in the study.
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